Search for content, post, videos

BioInvent terminates Phase II study

mikael oredsson bioinvent

BioInvent International announces that it has decided to terminate its current clinical Phase II study with BI-505 in multiple myeloma.

The decision follows BioInvent’s review and discussion with the US Food & Drug Administration (FDA), who put BI-505 on full clinical hold in November 2016.

The terminated trial, which was performed in collaboration with Penn Medicine, targeted a specific population of multiple myeloma patients undergoing autologous stem cell transplantation with high-dose melphalan.